KRAS

[Scientific Reports] The authors determined if mouse hepatic progenitor cells — oval cells (OCs) — were susceptible to incorporate Kras GAT mutation from mouse colorectal cancer cell line CT26.WT and if OCs with the incorporated mutation behaved like malignant cells.

[eLife] Tumor-associated macrophages (TAMs) are abundant, and they are important mediators of disease progression and invasion. Scientists generated tumor-educated macrophages in vitro and performed detailed, multiomic characterization.

[iScience] The authors found that Reh acute lymphoblastic leukemia cells bearing the KRAS-G12D mutation showed increased proliferation rates in vitro but displayed severely compromised growth in mice.

[Nature Cancer] Scientists performed a systematic high-throughput combination drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib, which targeted KRAS-directed oncogenic signaling in mesenchymal PDAC.

[Nature Communications] By utilizing a ΔNp63-specific conditional knockout mouse model and xenograft models of lung adenocarcinoma and squamous cell carcinoma, scientists found that ∆Np63 promoted NSCLC by maintaining the lung stem cells necessary for lung cancer cell initiation and progression in quiescence.

[Lung Cancer Research Foundation] The Lung Cancer Research Foundation (LCRF) and KRAS Kickers announced a partnership aimed at raising much needed funds for research. Together they to pledge to fund at least one two-year grant in 2022 with the goal of improving outcomes for people with KRAS-mutant lung cancer.